A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

Inclusion Criteria

• Pathologically confirmed, locally advanced or metastatic PDAC, CRC, or NSCLC with a KRAS G12D mutation
• Progressed on, or intolerant to at least one prior line of systemic standard of care therapy
• Measurable disease according to RECIST v1.1
• Adequate organ function

Exclusion Criteria

• Previous treatment with a KRAS G12D inhibitor or pan-RAS inhibitor
• History of intestinal disease, uncontrolled inflammatory bowel disease (e.g., Crohn's disease, Ulcerative Colitis), major esophageal or gastric surgery, or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study intervention or result in inability to swallow oral medications
• Poorly controlled ascites and/or pleural effusion
• Requires treatment with a strong and/or moderate CYP3A inhibitor or inducer
• Requires treatment with a proton-pump inhibitor